Market Overview - As of 10:30 AM today, the Shanghai Composite Index is at 3998.79 points, with a slight increase of 0.03% and total A-share trading volume reaching 1,083.642 billion yuan [1] Stocks Breaking Through Annual Line - A total of 76 A-shares have surpassed their annual line today, with notable stocks showing significant deviation rates including Binhai Energy at 8.36%, Overseas Chinese Town A at 6.04%, and Peking University Pharmaceutical at 5.58% [1] - The stocks with the largest deviation rates are as follows: - Binhai Energy: 9.96% increase, turnover rate of 4.54%, annual line at 11.51 yuan, latest price at 12.47 yuan [1] - Overseas Chinese Town A: 9.92% increase, turnover rate of 3.53%, annual line at 2.51 yuan, latest price at 2.66 yuan [1] - Peking University Pharmaceutical: 10.02% increase, turnover rate of 6.51%, annual line at 6.14 yuan, latest price at 6.48 yuan [1] Additional Stocks with Minor Deviations - Other stocks that have just crossed the annual line with smaller deviation rates include: - Shifeng Culture: 7.28% increase, turnover rate of 9.18%, annual line at 20.09 yuan, latest price at 20.92 yuan [1] - Shede Liquor: 3.72% increase, turnover rate of 2.05%, annual line at 59.70 yuan, latest price at 61.88 yuan [1] - Times Energy: 3.05% increase, turnover rate of 1.39%, annual line at 16.45 yuan, latest price at 16.92 yuan [1]

| | | 上海神奇制药投资管理股份有限公司 关于参加 2025 年上海辖区上市公司三季报集体业绩说 明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2025 年 11 月 13 日（星期四）15:00-16:30 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 11 月 12 日（星期三）16:00 前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司邮箱 shanghaiys@126.com 进行提问。公司将 在说明会上对投资者普遍关注的问题进行回答。 上海神奇制药投资管理股份有限公司（以下简称"公司"）已于 2025 年 10 月 31 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公 司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 13 日（星期 四）1 ...

Core Viewpoint - The company, Shenqi Pharmaceutical, is a well-known domestic pharmaceutical enterprise focusing on drug research, production, and sales, with a unique pharmaceutical technology and a rich product line [1] Group 1: Business Performance - For Q3 2025, Shenqi Pharmaceutical reported a revenue of 1.398 billion, ranking 42nd among 110 companies in the industry, with the industry leader, Huadong Medicine, generating 32.664 billion [2] - The net profit for the same period was 51.091 million, placing the company 63rd in the industry, while the top performer, Hengrui Medicine, achieved a net profit of 5.76 billion [2] Group 2: Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 21.93%, lower than the previous year's 24.56% and below the industry average of 35.26%, indicating good solvency [3] - The gross profit margin for Q3 2025 was 47.06%, down from 48.88% year-on-year and below the industry average of 57.17% [3] Group 3: Executive Compensation - The chairman, Zhang Taotao, received a salary of 36,000 for 2024, an increase of 5,000 from 2023 [4] - The general manager, Feng Bin, earned 528,000 in 2024, up by 47,700 from the previous year [4] Group 4: Shareholder Information - As of September 30, 2011, the number of A-share shareholders increased by 131.32% to 12,400, with an average holding of 8,238.31 circulating A-shares, an increase of 384.52% [5]

Core Viewpoint - The company, Shenqi Pharmaceutical, has disclosed a rectification report and an announcement regarding accounting errors, following a decision from the Shanghai Securities Regulatory Bureau due to discrepancies in its 2023 annual report [1] Financial Adjustments - The company has adopted a retrospective restatement method to adjust its 2023 financial data, reducing sales expenses from 909.41 million yuan by 44.84 million yuan to 864.57 million yuan, and credit impairment losses from 47.69 million yuan by 44.84 million yuan to 2.85 million yuan [1] - In the consolidated cash flow statement, cash received from sales was adjusted down from 2,124.00 million yuan by 44.84 million yuan to 2,079.16 million yuan, while cash received from other operating activities was increased by 44.84 million yuan to 266.39 million yuan [1] Recent Financial Performance - For the third quarter of 2025, the company reported revenue of 437 million yuan, a year-on-year decline of 3.51%, and a net profit attributable to shareholders of 17.49 million yuan, down 18.7% year-on-year [1] - The company's net profit excluding non-recurring items was 16.03 million yuan, reflecting a year-on-year decrease of 19.74%, with net cash flow from operating activities amounting to 110 million yuan [1]

Group 1 - The core point of the news is that Shenqi Pharmaceutical (600613.SH) reported its Q3 2025 results, revealing a total of 2 institutional investors holding 179 million shares, which accounts for 33.45% of the company's total equity [1] - The institutional investors include Guizhou Shenqi Holdings Group Co., Ltd. and Guizhou Maijisi Investment Management Co., Ltd., with a combined holding ratio of 33.45% [1] - Compared to the previous quarter, the total institutional holding ratio decreased by 0.51 percentage points [1] Group 2 - In the public fund sector, 29 public funds were disclosed this period, which were not reported in the previous quarter [1] - Notable public funds include Guojin Quantitative Multi-Factor A, Jinyuan Shun'an Yuanqi Flexible Allocation Mixed, Guojin Quantitative Selected A, Bodao Consumption Smart Navigation A, and Guotai Haitong CSI 1000 Index Enhanced A [1]

Core Viewpoint - The company reported a decline in both revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The total operating revenue for the first three quarters reached 1.398 billion yuan, representing a year-on-year decrease of 10.58% [1] - The net profit attributable to shareholders was 50.3016 million yuan, down 15.25% year-on-year [1] - The basic earnings per share stood at 0.09 yuan [1]

上海神奇制药投资管理股份有限公司 前期会计差错更正后的财务报表及附注 上海神奇制药投资管理股份有限公司（以下简称"公司"）于 2025 年 10 月 24 日召开第十一届董事会审计委员会 2025 年第四次会议、 2025 年 10 月 29 日召开第十一届董事会第十一次会议、第十一届监 事会第十次会议，审议通过了《关于上海证监局对公司采取责令改正 措施的整改报告和前期会计差错更正及追溯调整的议案》，同意公司 根据《企业会计准则第 28 号——会计政策、会计估计变更和差错更 正》、《公开发行证券的公司信息披露编报规则第 19 号——财务信息 的更正及相关披露》等相关文件的规定，对前期相关会计差错进行更 正。现将更正后的相关财务报表及附注披露如下：（粗体字数字为本 次差错更正受影响数据） 一、2023 年度更正后的财务报表 （一）合并利润表 合并利润表 2023 年度 金额单位：人民币元 | 项目 | 本期金额 | 上期金额 | | --- | --- | --- | | 一、营业总收入 | 2,340,945,518.00 | 2,388,617,677.74 | | 其中：营业收入 | 2,340,945, ...

一、运营数据 1．主营业务分行业情况 单位：元 2．主营业务分类情况 单位：元 证券代码：A 股 600613 股票简称：A 股 神奇制药 编号：2025-037 B 股 900904 B 股 神奇 B 股 上海神奇制药投资管理股份有限公司 2025 年三季度主要运营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | | | | | 营业收入 | | 毛利率 | | --- | --- | --- | --- | --- | --- | --- | | 分产品 | 营业收入 | 营业成本 | 毛利率 | 比上年同 | 营业成本 比上年同 | 比上年 同期增 | | | | | （%） | 期增减 | | | | | | | | （%） | 期增减（%） | 减百分 | | | | | | | | 点 | | 抗肿瘤药 系列 | 387,676,903.77 | 47,684,697.25 | 87.70 | -5.14 | 3.73 | -1.05 | | 皮肤外用抗菌 | 67,252,647.99 | 9, ...

证券代码：A 股 600613 股票简称：A 股 神奇制药 编号： 2025-035 B 股 900904 B 股 神奇 B 股 1．公司 2025 年第三季度报告及摘要的编制和审议程序符合法律、法规、《公 司章程》和公司内部管理制度的各项规定。 2．公司 2025 年第三季度报告及摘要的内容和格式符合中国证监会和上海证 券交易所的各项规定，所包含的信息能全面、真实地反映出公司的经营管理和财 务状况等事项。 3．公司监事会在提出审核意见前，没有发现参与公司 2025 年第三季度报告 及摘要编制和审议的人员有违反保密规定的行为。 一 、 同 意 《 公 司 2025 年 第 三 季 度 报 告 》（ 全 文 详 见 上 交 所 网 站 ： http://www.sse.com.cn）。 监事会一致认为： 4．全体监事保证公司 2025 年第三季度报告及摘要所披露的信息真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性和完整性承担个别及连带责任。 同意票 3 票，反对票 0 票，弃权票 0 票 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏， ...

| 证券代码：A 股票简称：A | | | | | --- | --- | --- | --- | | 股 股 | | | | | 600613 900904 | | | | | | 股 股 | 神奇制药 神奇 B | | | | | 股 | 编号：2025-034 | | B | B | | | 董事会审计委员会提前审议了公司关于本次前期会计差错更正情况并沟通 讨论，认为本次前期会计差错更正及追溯调整事项符合《企业会计准则第 28 号 ——会计政策、会计估计变更和差错更正》《公开发行证券的公司信息披露编报 规则第 19 号——财务信息的更正及相关披露》等有关规定和要求，一致同意通 过该议案，并同意提交公司董事会审议。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海神奇制药投资管理股份有限公司（以下简称"公司"）第十一届董事会 第十一次会议通知已于 2025 年 10 月 24 日分别以送达、传真、邮件等方式通知 公司董事、监事。会议于 2025 年 10 月 29 日以通讯表决方式召开。会议应参加 表决董事 9 ...